Research Grade Emfizatamab

Primary

CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain, Tumor necrosis factor receptor superfamily member 9, CD137, 4-1BB ligand receptor, CDw137, TNFRSF9, T-cell antigen ILA, T-cell antigen 4-1BB homolog, ILA

0.01M PBS, pH 7.4.

For research use only. Not suitable for clinical or therapeutic use.

1 mg/ml

Mammalian Cells